BioNet和Bio Farma签署战略谅解备忘录，扩大东盟地区TdaP疫苗的获取途径-动脉网

BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN

CISION 等信源发布 2025-06-03 20:43



可切换为仅中文







JAKARTA, Indonesia

印度尼西亚雅加达

，

June 3, 2025

2025年6月3日

/PRNewswire/ -- BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero),

/PRNewswire/ -- 法国-泰国疫苗生物技术集团BioNet与PT Bio Farma（Persero），

Indonesia's

印度尼西亚的

state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).

国有企业疫苗制造商，已签署谅解备忘录（MoU），就联合开发和区域分销联合TdaP疫苗（破伤风、白喉和无细胞重组百日咳）进行合作。

继续阅读

BioNet and Bio Farma

BioNet 和 Bio Farma

BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN

BioNet和Bio Farma签署战略谅解备忘录，扩大东盟地区TdaP疫苗的获取途径

Signed during the State Visit of French President

签署于法国总统国事访问期间

Emmanuel Macron

埃马纽埃尔·马克龙

至

Indonesia

印度尼西亚

, the agreement underscores a commitment to accelerating access to innovative vaccines across

，该协议强调了加速获取创新疫苗的承诺

Southeast Asia

东南亚

. The partnership combines BioNet's proprietary recombinant pertussis technology and global clinical experience with Bio Farma's large-scale manufacturing and public health reach to address critical immunization needs in ASEAN.

该合作伙伴关系结合了BioNet专有的重组百日咳技术和全球临床经验，以及Bio Farma的大规模制造能力和公共卫生覆盖范围，以满足东盟地区的紧急免疫需求。

'This agreement reflects our shared goal to make next-gen vaccines accessible where needed most,' said Philippe Guillot-Chêne, CEO of BioNet Europe. 'By aligning our strengths, BioNet and Bio Farma strengthen the regional health ecosystem and ASEAN's capacity to respond to current and emerging infectious disease threats.'.

“该协议反映了我们共同的目标，即在最需要的地方提供下一代疫苗，”BioNet欧洲公司首席执行官菲利普·吉约-谢纳表示。“通过结合我们的优势，BioNet和Bio Farma加强了区域健康生态系统以及东盟应对当前和新兴传染病威胁的能力。”

The MoU outlines cooperation in clinical development, regulatory alignment, and market access. Bio Farma leads clinical trials and regulatory submissions in

谅解备忘录概述了在临床开发、监管协调和市场准入方面的合作。Bio Farma领导临床试验和监管提交工作。

Indonesia

印度尼西亚

, while BioNet handles other ASEAN countries. The collaboration aims to reduce vaccine introduction from 10–15 years to less than five.

，而BioNet则负责其他东盟国家。此次合作旨在将疫苗引进时间从10到15年缩短至不到5年。

'Through this collaboration, we are reinforcing

“通过这次合作，我们正在加强

Indonesia's

印度尼西亚的

commitment to regional vaccine self-sufficiency and innovation,' said Yuliana Indriati, Director of Business Development at Bio Farma. 'With BioNet's advanced recombinant pertussis technology and our production capacity, we aim to ensure timely access to TdaP vaccines for Indonesian adolescents, pregnant women, and the elderly.

Bio Farma业务发展总监尤莉安娜·因德里亚蒂表示：“我们致力于区域疫苗自给自足和创新。通过BioNet先进的重组百日咳技术以及我们的生产能力，我们的目标是确保印尼青少年、孕妇和老年人能够及时获得TdaP疫苗。”

We hope this product will soon be part of our immunization program.'.

我们希望该产品能尽快成为我们免疫计划的一部分。

The TdaP vaccine combines Bio Farma's Td and BioNet's aP antigens. It targets the ASEAN market with an estimated 10–15 million doses annually, valued at around

TdaP疫苗结合了Bio Farma的Td和BioNet的aP抗原。它面向东盟市场，预计每年供应1000万至1500万剂，价值约

USD 200 million

2亿美元

。

This partnership aims to strengthen pandemic preparedness, build resilient vaccine supply chains, and improve equitable healthcare access across

该合作伙伴关系旨在加强大流行病的准备、建立有弹性的疫苗供应链，并改善整个地区的公平医疗保健获取。

Southeast Asia

东南亚

。

This step aligns with President Prabowo Subianto's

这一举措符合普拉博沃·苏比安托总统的立场。

Asta Cita

阿斯塔·奇塔

, particularly the goals of national self-reliance in economy, food, and energy, improving quality of life, and expanding access to affordable, high-quality healthcare.

，特别是实现经济、粮食和能源的国家自力更生、改善生活质量以及扩大获得负担得起的高质量医疗保健的机会等目标。

About BioNet

关于BioNet

BioNet is a French-Thai vaccine organization developing and manufacturing genetically designed vaccines with a global footprint. The group includes:

BioNet是一家法泰疫苗组织，致力于开发和生产基因设计的疫苗，业务遍布全球。该集团包括：

BioNet Europe, which submitted an EU-GMP recombinant pertussis vaccine application to the EMA.

向欧洲药品管理局提交了欧盟良好生产规范重组百日咳疫苗申请的BioNet Europe。

BioNet Asia, based in

亚洲生物网，总部位于

Thailand

泰国

, producing the world's only standalone recombinant pertussis vaccine.

，生产世界上唯一的独立重组百日咳疫苗。

BioNet has developed a clinically validated mRNA platform, enabling partnerships for technology transfer, regional manufacturing, and pandemic preparedness.

BioNet 开发了一个经过临床验证的 mRNA 平台，可实现技术转让、区域制造和大流行病预防的合作。

About Bio Farma

关于Bio Farma

PT Bio Farma (Persero) is

印尼生物制药公司（Persero）是

Indonesia's

印度尼西亚的

largest state-owned pharmaceutical holding company, offering integrated services from R&D and manufacturing to distribution, retail pharmacies, clinics, and labs. Its head office and manufacturing site are in Bandung,

最大的国有制药控股公司，提供从研发、生产到分销、零售药店、诊所和实验室的一体化服务。其总部和生产工厂位于万隆，

West Java

西爪哇省

, with a representative office in

，设有代表处位于

Jakarta

雅加达

. With over 3.2 billion vaccine doses produced annually, Bio Farma exports to more than 150 countries. It is the parent of two listed firms on the Indonesia Stock Exchange: PT Kimia Farma Tbk (KAEF) and PT Indofarma Tbk (INAF). More info:

每年生产超过32亿剂疫苗，Bio Farma出口到150多个国家。它是印尼证券交易所两家上市公司的母公司：PT Kimia Farma Tbk（KAEF）和PT Indofarma Tbk（INAF）。更多信息：

www.biofarma.co.id

。

For press information, kindly contact:

如需新闻资讯，请联系：

PT Bio Farma (Persero)

印尼生物制药公司（Persero）

Zaki Zakaria

扎基·扎卡里亚

Corporate Communication

企业沟通

BioNet Europe